Benefit of Apabetalone on Plasma Proteins in Renal Disease

INTRODUCTION: Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone has in vitro and in vivo anti-inflammatory and antiatherosclerotic properties. In phase 2 clinical trials, this drug reduced the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Kidney Int Rep
Main Authors: Wasiak, Sylwia, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Gilham, Dean, Jahagirdar, Ravi, Kalantar-Zadeh, Kamyar, Robson, Richard, Sweeney, Michael, Johansson, Jan O., Wong, Norman C., Kulikowski, Ewelina
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2017
Teme:
Translational Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5976837/
https://ncbi.nlm.nih.gov/pubmed/29854980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2017.12.001
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki